LyGenesis adds inborn metabolism errors to drug pipeline

Grandparent

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

LyGenesis adds orphan paediatric indications with large unmet needs to its drug development pipeline with novel approach which first aims to treat paediatric patients with Maple syrup urine disease.

LyGenesis, a clinical-stage biotechnology company developing cell therapies for patients with end stage liver disease, Type 1 diabetes, end stage renal disease and aging, announced today that it has achieved positive in vitro results of a novel combination drug-biologic product for patients with inborn errors of metabolism, adding these orphan pediatric indications to its drug development pipeline.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 2260

LyGenesis

Longevity level(s):

  • Level 7: Targeted aging disease reversal
    Therapeutic interventions that stop or reverse age-related damage in specific organs (organ specific / tissue specific / localized reversal) or for age-related diseases including technologies like partial cellular reprogramming.
  • Level 8: Systemic aging reversal
    Therapeutic interventions that stop or reverse age-related damage throughout the whole body system at a cellular level. Including technologies such as mitochondrial transplant, senotherapeutics and partial cellular reprogramming.

Overview

LyGenesis is a clinical-stage regenerative medicine company developing a novel platform that leverages the body’s own lymph nodes as biological bioreactors to grow functioning ectopic organs. Using minimally invasive delivery of allogeneic donor cells, the company is advancing therapies designed to restore organ function and address diseases associated with organ failure, metabolic dysfunction, immune decline, and aging. Unlike traditional transplantation approaches, LyGenesis’ proprietary technology enables a single donor organ to potentially treat up to 50 patients, creating a scalable regenerative medicine solution that addresses the global shortage of transplantable organs while significantly expanding patient access. The platform is being developed across liver, pancreas, thymus, and kidney applications with therapeutic potential spanning end-stage organ disease, Type 1 diabetes, immune tolerance induction, immune system rejuvenation, and age-related degenerative conditions. By combining scalable manufacturing, minimally invasive delivery, and a novel approach that leverages the body’s own regenerative capacity, LyGenesis is developing a platform that has the potential to expand access to organ replacement therapies while addressing broader applications in immune function, metabolic disease, and age-related decline.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

Eleanor Garth

Editor

Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

With a keen interest in all things geroscience, Eleanor covers the biological mechanisms of aging, highlighting how interventions – from nutritional strategies to advanced therapeutics – can influence the aging process at a cellular level. She also investigates the broader implications of aging research, including the integration of longevity science into healthcare strategy and the expanding wellness economy. Her work (hopefully) provides insights into how these developments are shaping the emerging landscape of healthspan optimization and age-related innovation.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Beauty giant and supplement startup both chase skin aging

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE